<DOC>
	<DOCNO>NCT00306384</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety alogliptin , daily ( QD ) , follow participation 1 7 controlled study patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>Long-term Safety Alogliptin Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>SYR-322 ( alogliptin ) inhibitor dipeptidyl peptidase IV enzyme . Dipeptidyl peptidase IV think primarily responsible degradation 2 peptide hormone release response nutrient ingestion , namely glucagon-like peptide-1 glucose-dependent insulinotropic peptide . It expect inhibition dipeptidyl peptidase IV improve glycemic ( glucose ) control patient type 2 diabetes mellitus prolong beneficial effect glucagon-like peptide-1 . The rise incidence type 2 diabetes mellitus limitation currently available treatment suggest need new therapy glycemic control . Studies undertake human evaluated effect directly augment glucagon-like peptide-1 glucose-dependent insulinotropic peptide level inhibit activity dipeptidyl peptidase IV . This study extension 7 control phase 3 study alogliptin . These phase 3 study include 1 monotherapy study alogliptin ( SYR-322-PLC-010 ; NCT00286455 ) ; 4 placebo-controlled add-on study alogliptin , namely combination sulfonylurea ( SYR-322-SULF-007 ; NCT00286468 ) , metformin ( SYR-322-MET-008 ; NCT00286442 ) , thiazolidinedione ( pioglitazone ; SYR-322-TZD-009 ; NCT00286494 ) , insulin ( SYR-322-INS-011 ; NCT00286429 ) ; 1 coadministration study pioglitazone combination metformin ( 01-05-TL-322OPI-001 ; NCT00328627 ) , 1 coadministration study pioglitazone ( 01-06-TL-322OPI-002 ; NCT00395512 ) . The end treatment early withdrawal visit precede study screen visit study , enrol patient require commit approximately 22 additional visit study center .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<criteria>Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study . Type 2 diabetes mellitus enrol one follow 7 controlled Phase III study . The study open patient complete one study endoftreatment visit : SYR322PLC010 NCT00286455 SYR322SULF007 NCT00286468 SYR322MET008 NCT00286442 SYR322TZD009 NCT00286494 SYR322INS011 NCT00286429 0105TL322OPI001 NCT00328627 0106TL322OPI002 NCT00395512 Alanine aminotransferase less equal 3 time upper limit normal serum creatinine less equal 2.0 mg per dL . Able willing monitor blood glucose concentration home glucose monitor . No major illness debility investigator 's opinion prohibit patient complete study . Exclusion Criteria The occurrence adverse event condition control Phase III study , , opinion investigator , exclude patient participate openlabel extension . Is required take intend continue take disallowed medication , prescription medication , herbal treatment overthe counter medication may interfere evaluation study medication , include : Weightloss drug Investigational antidiabetic , additional dipeptidyl peptidase4 ( DPP4 ) glucagonlike peptide1 ( GLP 1 ) inhibitor Incretin Mimetics , Oral systemically inject glucocorticoid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Glucose Metabolism Disorder</keyword>
	<keyword>Dysmetabolic Syndrome</keyword>
	<keyword>Type II Diabetes</keyword>
	<keyword>Diabetes Mellitus ,</keyword>
	<keyword>Lipoatrophic</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>